Mirum Pharmaceuticals Company Description

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.

Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis.

In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases.

The company was incorporated in 2018 and is headquartered in Foster City, California.

Mirum Pharmaceuticals, Inc.

Country	United States
Founded	2018
Industry	Biological Products, Except Diagnostic Substances
Employees	322
CEO	Christopher Peetz

Contact Details

Address: 950 Tower Lane Foster City, Delaware 94404 United States
Phone	650 667 4085
Website	mirumpharma.com

Stock Details

Ticker Symbol	08D
Exchange	Frankfurt Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
Christopher Peetz	Chief Executive Officer
Eric Bjerkholt	Chief Financial Officer
Peter Radovich	Chief Operating Officer
Andrew McKibben	Head of Investor Relations